Quick Answer
Emmaus Life Sciences, Inc. reported Operating Income Loss of $231.0 thousand for the year ending 2025.
- Emmaus Life Sciences, Inc. showed an increase of +112.2% in Operating Income Loss from 2024 to 2025.
- This data is from Emmaus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: -$1.43 million | Q1 2012: -$1.33 million | Q2 2012: -$1.15 million | Q4 2012: -$698.9 thousand | Q1 2013: -$1.12 million | Q2 2013: -$1.18 million | Q4 2013: -$963.9 thousand | Q1 2014: -$940.7 thousand | Q2 2014: -$1.01 million | Q4 2014: -$779.2 thousand | Q1 2015: -$780.1 thousand | Q2 2015: -$556.0 thousand | Q4 2015: -$624.7 thousand | Q1 2016: -$690.0 thousand | Q2 2016: -$809.2 thousand | Q4 2016: -$1.44 million | Q1 2017: -$1.42 million | Q2 2017: -$1.55 million | Q4 2017: -$2.76 million | Q1 2018: -$2.63 million | Q2 2018: -$2.91 million | Q3 2018: -$2.13 million | Q4 2018: -$2.68 million | Q1 2019: -$1.28 million | Q2 2019: $116.0 thousand | Q3 2019: -$4.05 million | Q1 2020: $1.13 million | Q2 2020: -$1.54 million | Q3 2020: $8.0 thousand | Q1 2021: -$1.62 million | Q2 2021: $483.0 thousand | Q3 2021: -$31.0 thousand | Q1 2022: -$3.07 million | Q2 2022: -$1.44 million | Q3 2022: -$660.0 thousand | Q1 2023: -$1.17 million | Q2 2023: $3.33 million | Q3 2023: $24.0 thousand | Q1 2024: -$2.74 million | Q2 2024: $582.0 thousand | Q3 2024: $821.0 thousand | Q1 2025: -$980.0 thousand | Q2 2025: -$370.0 thousand | Q3 2025: $695.0 thousand.
- Over the full 16 years of available data (2011 to 2025), Emmaus Life Sciences, Inc.'s Operating Income Loss has grown by 104.4%.
- Historical annual values: Fiscal year 2025: $231.0 thousand | Fiscal year 2024: -$1.89 million | Fiscal year 2023: $3.54 million | Fiscal year 2022: -$6.59 million | Fiscal year 2021: -$6.13 million | Fiscal year 2020: -$32.0 thousand | Fiscal year 2019: -$4.51 million | Fiscal year 2018: -$8.45 million | Fiscal year 2018: -$10.24 million | Fiscal year 2017: -$7.10 million | Fiscal year 2016: -$3.77 million | Fiscal year 2015: -$2.65 million | Fiscal year 2014: -$3.82 million | Fiscal year 2013: -$4.20 million | Fiscal year 2012: -$4.81 million | Fiscal year 2011: -$5.29 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: